Injectable GHK-CU and BPC157 were discussed for hair loss, but users did not notice significant hair changes. BPC157 was noted to help with shoulder issues.
PP405 is a safer alternative to JXL069 for hair loss treatment because it penetrates the skin effectively and degrades in the blood, avoiding systemic toxicity. JXL069, when forced into the body, can cause dangerous side effects like lactic acidosis due to its inability to degrade safely.
A user underwent a second hair transplant for increased density and to address hair loss in the crown area, with 3,800 grafts at a cost of 2,200 euros at Estepalace, including additional services. Some commenters discussed the appearance of the hairline and the importance of using DHT blockers like finasteride or dutasteride post-transplant.
The conversation discusses the use of dutasteride and finasteride for hair loss, including switching between them, optimal dosing, and managing side effects. The user has transcriptions of videos on these topics and offers them to others interested.
The user is concerned about the quick prescription process for hair loss treatments like Minoxidil and Finasteride through HIMs, questioning the lack of a thorough evaluation. Another user reassures that such practices are common, emphasizing the effectiveness and low risk of these treatments, and suggests monitoring personal response to the medication.
OP shared an 8-month update on hair transplant results, using Dutasteride, oral Minoxidil, and Biotin. OP also discussed a simple skincare routine with Cerave products and sunscreen.
The conversation is about when GT20029, a hair loss treatment, might be available on the grey market, with users discussing the challenges of compounding it and speculating it might be available after phase 2 results, similar to pyri. Specific treatments mentioned are pyri, RU58841, and GT20029.
The conversation is about a user's comprehensive hair loss treatment plan, including finasteride, minoxidil, dermaroller, Nizoral shampoo, vitamin D, biotin, and zinc. The user describes their approach as a strategic battle against DHT, with finasteride as the main treatment.
The conversation is about the effectiveness and production of GT20029, a drug being developed as a topical androgen receptor degrader for hair loss, and whether it can fully degrade androgen receptors or only partially. It also discusses the drug's potential unique working mechanism and synthesis by a company called Anagen.
The conversation discusses using microneedling with copper peptides, specifically GHK-Cu, for hair loss treatment. Some users combine it with minoxidil and topical finasteride, applying peptides either topically or through injection.
A user is seeking feedback on a homemade topical finasteride formula for hair loss, consisting of 7.5 mg of finasteride, propylene glycol, ethanol, and distilled water. They aim to achieve a 0.0125% solution by applying 2 ml daily.
A user shared progress pictures after 5 months using Hims 2-in-1 finasteride and minoxidil with a 1.5mm derma roller. Other users commented positively and shared their own experiences with the treatment.
A user shared an 8-month update on hair regrowth using HIMS fin/min spray and dermastamping every two weeks, showing significant improvement. Others commented on their own progress and hopes for similar results.
GHK-Cu and Acetyl Tetrapeptide-3 are ineffective for hair regrowth according to user experiences. Effective treatments mentioned are finasteride, dutasteride, and minoxidil.
The conversation is about finding an affordable and effective low level laser therapy device for hair loss, with a preference for a cap but open to a comb.
The user is experiencing diffuse androgenic alopecia and is trying various treatments, including 5mg finasteride, loniten, and Formula 82D, which contains dutasteride, a steroid, and tretinoin. They report potential regrowth with Formula 82D, despite previous treatments being ineffective.
Dutasteride, taken every other day with vitamin and mineral supplements, successfully increased crown hair density without side effects after seven months. The user plans to leave the subreddit after achieving desired hair regrowth.
User shared 12-month hair loss progress using oral minoxidil, oral dutasteride, and 2% ketoconazole shampoo. They detailed their medication regimen and dosages.
VDPHL01 shows faster and stronger hair growth compared to standard minoxidil, with no major side effects reported. Users discuss combining it with other treatments like dutasteride and finasteride for better results, while expressing skepticism about the effectiveness of PP405.
PP405 is seen as a potential breakthrough for converting vellus hairs to terminal hairs, with users expressing both hope and skepticism. It is compared to treatments like minoxidil and finasteride, with discussions on side effects and marketing concerns.
SCUBE3 and Amplifica's progress in hair loss treatment is being discussed, with inquiries about their current status and clinical trials. No specific updates or new information are provided in the conversation.
L'Oreal is working on hair cloning, with multiple companies using similar techniques, making hair cloning likely by 2030. The conversation expresses optimism about the progress and potential affordability of hair cloning solutions.
The conversation is about disappointment with pyrilutamide's performance as a hair loss treatment, with some users expressing interest in other treatments like Verteporfin, GT20029, and RU58841, while others suggest sticking with established treatments like finasteride or dutasteride.
A user is making a 2-Deoxy-D-ribose solution and asks if it can be put into an oil instead of a gel, considering adding hydrocortisone and retinoic acid. They seek advice on the best carrier oil for hair growth.
The user successfully improved their hair from Norwood 3 to 0.5 using finasteride, topical minoxidil, microneedling, and a hair peptide, and plans to maintain it with dutasteride. They are leaving the forum due to emotional distress caused by the community.
The conversation is about selling KY19382 powder, a novel activator of Wnt/β-catenin signaling, and Kolliphor EL liquid for vehicle formulation. The seller offers worldwide shipping.